GSK plc (LON:GSK) Insider Emma Walmsley Sells 120,653 Shares of Stock

GSK plc (LON:GSK) insider Emma Walmsley sold 120,653 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.09), for a total transaction of £1,753,088.09 ($2,182,086.25).

GSK Stock Performance

LON GSK opened at GBX 1,445 ($17.99) on Thursday. The stock has a 50-day moving average of GBX 1,363.57 and a two-hundred day moving average of GBX 1,455.91. The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73. The company has a market cap of £58.96 billion, a P/E ratio of 1,278.76, a P/E/G ratio of 1.24 and a beta of 0.31. GSK plc has a 1-year low of GBX 1,282.50 ($15.96) and a 1-year high of GBX 1,823.50 ($22.70).

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter. GSK had a return on equity of 33.30% and a net margin of 12.83%. As a group, analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank reduced their price target on GSK from GBX 1,820 ($22.65) to GBX 1,600 ($19.92) and set a “buy” rating on the stock in a report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus price target of GBX 1,805.83 ($22.48).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.